Amryt Pharma PLC

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded in August 2015 and is headquartered in Dublin, Ireland.

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2 nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

DUBLIN, Ireland, and Boston MA, March 31, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce its support for World Lipodystrophy Day 2022 which takes place today.

Amryt Supports World Lipodystrophy Day - March 31, 2022

Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB

NEW YORK , March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amryt Pharma plc ("Amryt" or the "Company") (NASDAQ: AMYT).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amryt Pharma plc - AMYT

Amryt Pharma (AMYT) CEO Dr. Joe Wiley on Q4 2021 Results - Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Amryt Pharma plc (“Amryt ” or the “Company”) (NASDAQ: AMYT) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Amryt investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, y

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Amryt Pharma plc (AMYT) on Behalf of Investors

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 207.14% and 3.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma PLC Sponsored ADR (AMYT) Tops Q4 Earnings Estimates

Amryt Announces 22% growth in FY 2021 Revenues to $222.5M

NEW YORK--(BUSINESS WIRE)-- #Amryt--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Amryt Pharma plc (“Amryt Pharma” or the “Company”) (NASDAQ: AMYT) on behalf of Amryt Pharma stockholders. Our investigation concerns whether Amryt Pharma has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On February 28, 2022, Amryt Pharma issued a press relea

AMRYT PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating Amryt Pharma plc on Behalf of Amryt Pharma Stockholders and Encourages Investors to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Amryt Pharma plc (“Amryt” or the “Company”) (NASDAQ: AMYT) investors concerning the Company's possible violations of federal securities laws. On February 28, 2022, Amryt disclosed receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) stating that the Company's New Drug Application for its Dystrophic and Junctional Epidermolysis Bullosa (“EB”) treatmen

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amryt Pharma plc (AMYT) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Amryt Pharma plc (“Amryt ” or the “Company”) (NASDAQ: AMYT) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 28, 2022, Amryt disclosed receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) stating that the Company's New Drug Applic

The Law Offices of Frank R. Cruz Announces Investigation of Amryt Pharma plc (AMYT) on Behalf of Investors

Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules )

Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules)

NEW YORK--(BUSINESS WIRE)---- $AMYT--The law firm of Kirby McInerney LLP is investigating potential claims against Amryt Pharma plc (“Amryt Pharma” or the “Company”) (NASDAQ: AMYT). The investigation concerns whether Amryt Pharma has violated the federal securities laws and/or engaged in other unlawful business practices. Amryt Pharma operates as a biopharmaceutical company. The Company develops and delivers treatments for rare and orphan diseases. On February 28, 2022, Amryt Pharma issued a press releas

Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Amryt Pharma plc (AMYT) Investors

Amryt Pharma (AMYT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Amryt Pharma (AMYT) Might Surprise This Earnings Season

Amryt Pharma PLC Sponsored ADR (AMYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 N D A

Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA

Amryt Pharma Plc (NASDAQ: AMYT) has received a Complete Response Letter (CRL) from the FDA regarding Oleogel-S10 application for cutaneous manifestations of Dystrophic and Junctional Epidermolysis Bullosa (EB). EB is a rare, genetic skin disease characterized by extremely fragile.

FDA Rejects Amryt Pharma's Oleogel-S10 Application For Skin Blistering Disorder

Amryt Supports Rare Disease Day 2022

A mryt to Report FY and Q4 202 1 Results on March 9, 2022

Amryt to Report FY and Q4 2021 Results on March 9, 2022

Amryt Completes $125 Million Non-Dilutive Debt Ref inancing

Amryt Completes $125 Million Non-Dilutive Debt Refinancing

The European Medicines Agency plans to seek external independent Epidermolysis Bullosa (EB) specific expertise and advice on assessing Amryt Pharma Plc's  AMYT Oleogel-S10. [ALERT[ Matt Maley just released his latest pick with an upside of over 100% in 2 years.

Amryt Shares Fall After Oleogel-S10 EMA Regulatory Update

Amryt Announces Oleogel-S10 EMA Regulatory Update

Amryt Pharma PLC Sponsored ADR (AMYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Amryt Pharma PLC Sponsored ADR (AMYT) Surges 5.5%: Is This an Indication of Further Gains?

Amryt Announces New Patents for Oleogel-S10

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

News for Amryt Pharma PLC Stock (AMYT)